
==== Front
Cell Mol Life Sci
Cell Mol Life Sci
Cellular and Molecular Life Sciences: CMLS
1420-682X
1420-9071
Springer International Publishing Cham

5412
10.1007/s00018-024-05412-y
Review
Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
Li Jing
Zhou Weilin
http://orcid.org/0000-0001-7788-1895
Wang Wei weiwang@scu.edu.cn

grid.13291.38 0000 0001 0807 1581 Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041 People’s Republic of China
31 8 2024
31 8 2024
12 2024
81 1 37828 4 2024
10 8 2024
12 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Adoptive cell therapy (ACT) achieves substantial efficacy in the treatment of hematological malignancies and solid tumours, while enormous endeavors have been made to reduce relapse and extend the remission duration after ACT. For the genetically engineered T cells, their functionality and long-term anti-tumour potential depend on the specificity of the T cell receptor (TCR) or chimeric antigen receptor (CAR). In addition, the therapeutic benefit is directly to sufficient activation and proliferation of engineered T cells. Artificial antigen-presenting cells (aAPCs), as powerful boosters for ACT, have been applied to provide sustained stimulation of the cognate antigen and facilitate the expansion of sufficient T cells for infusion. In this review, we summarize the aAPCs used to generate effector cells for ACT and underline the mechanism by which aAPCs enhance the functionality of the effector cells. The manuscript includes investigations ranging from basic research to clinical trials, which we hope will highlight the importance of aAPCs and provide guidance for novel strategies to improve the effectiveness of ACT.

Keywords

Adoptive cell therapy (ACT)
Cancer immunotherapy
Artificial antigen-presenting cells (aAPCs)
Challenge and development
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China http://dx.doi.org/10.13039/501100012165 Key Technologies Research and Development Program http://dx.doi.org/10.13039/501100018525 Key Research and Development Program of Sichuan Province issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

Adoptive cell therapy (ACT) is a promising new treatment option for hematological diseases and solid tumours with limited treatment options [1–3]. ACT involves inducing, activating, or genetically engineering anti-tumour lymphocytes from patients or healthy donors in vitro, then returning them to the patients to recognize and eliminate tumour cells. Generating sufficient functional engineered T cells is a prerequisite for achieving promising therapeutic efficacy, which is largely determined by the in vitro activation and expansion steps. In vivo, these processes are enhanced by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages, and B cells [4–7]. However, the isolation and purification of autologous APCs can be labour-intensive. Furthermore, their utilization is often hindered by the lack of consistency and standardization in terms of cell number and phenotype. In this context, artificial antigen-presenting cells (aAPCs) have been developed with the aim of enabling more efficient and reproducible ex vivo activation and expansion of T cells. aAPC refers to both acellular and cell-based aAPC [8–10]. In this manuscript, we compare the advantages and limitations of cell-based and acellular aAPC. We argue that cell lines, once generated and stored, offer an advantage over autologous APC, which cannot be stored for long periods of time, by providing a long-term, reliable source of reagents for T cell generation or expansion. One significant advantage of cellular aAPCs over non-cellular is their capacity to effectively emulate the natural physiologic interaction between T cells and APCs. These interactions are essential for aAPC signalling of T cells [11]. We believe that cell-based aAPC, offering considerable promise, is desirable for immunotherapy. To date, a variety of aAPCs with different designs and properties have been synthesized and demonstrated to be highly efficacious in T cell activation for clinical applications. Despite considerable progress, the current development of aAPCs still faces challenges, including limited specificity and effectiveness, overstimulation, rapid exhaustion, and a lack of sustained cytokine release. To enhance the efficacy and accessibility of ACT, the development of a more efficient and safer APC represents a pivotal and immediate objective. Herein, we summarize recent advances in cell-based aAPC for both ex vivo and in vivo applications in ACT.

Natural biological signals of the immune system utilized by aAPC

The activation of T lymphocytes is a hallmark of the immune response [12]. Dual-signal stimulation is required to trigger T cell activation, proliferation and differentiation into effector T cells. The initial signal is mediated by the major histocompatibility complex (MHC) peptide complex (signal 1) and amplified by adhesion molecules [13]. The co-stimulatory signal (signal 2) is generated by the interaction between APCs and T cells [14, 15], which can enhance the T cell receptor (TCR) signal. The surface synergistic stimulatory molecules of APCs play an essential role in this process. Cytokines (signal 3) are also pivotal biological determinants of T cell expansion, survival, and function [16, 17]. The aforementioned T cell activation signals can be reconstituted by expressing the appropriate ligand combinations in the aAPC (Fig. 1). Subsequently, we will present how distinct combinations of ligand constructs on aAPC can regulate the functions of T cells.

Signal 1: T-cell specific proliferation signal

The function of the MHC or human leukocyte antigen (HLA) is to bind and present antigen peptides for recognition by T cells. MHC class I molecules are responsible for the combination and presentation of endogenous antigen peptides following proteasome treatment in the endoplasmic reticulum. The peptide is combined with MHC class I molecules to form a complex (pMHC), then presented to the cell surface [18]. After the TCR recognizes a specific pMHC, CD8+ T cells are activated and subsequently transformed into active cytotoxic T lymphocytes. These cells are responsible for the killing of target cells. MHC class II molecules are responsible for the presentation of exogenous antigen peptides to CD4+ T cells, allowing CD4+ T cells to activate, proliferate and express appropriate lymphokines [19]. Multiple studies have demonstrated that aAPCs expressing HLA-class I molecule can maintain the proliferation of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs). Furthermore, these CTLs are able to identify and effectively kill tumour cell targets when HLA-restriction is in place [20]. This strategy has been validated in the clinical trial stage. The MART1-specific CTL generated by aAPCs, transduced with CD80, CD83 and HLA-A * 0201 can persist in vivo and induce anti-tumour response [21, 22]. Several pieces of evidence show that CD4+ T cells contribute to the generation of optimal anti-tumour CD8+ T cell responses and the establishment of long-lasting memory [19, 23]. Consequently, researchers have developed aAPC expressing MHC class II molecules for the expansion of CD4+ T cells [24, 25]. For instance, aAPCs engineered based on K562 cells express different single HLA-DR alleles, invariant chains, and HLA-DM. These aAPCs can absorb soluble proteins by endocytosis and process and present peptides [26]. The novel tool was employed to amplify long-acting CD4+ T cells with specificity for multiple antigens, while preventing the growth of Foxp3+ regulatory T cells [26]. Chimeric antigen receptor T (CAR-T) cells harness extracellular single-chain variable regions (scFv) to recognize tumour antigens, initiate intracellular signals and eliminate tumour cells. The scFv is composed of the variable heavy chain and variable light chain from the specific antibody. It is capable of recognizing tumour cell surface antigens, leading to MHC-independent activation of T-cells. The genes cargo encoding tumour antigens were introduced into aAPC, which facilitates the proliferation of CAR-specific T cells. For example, multiple aAPCs expressing CD19 molecules have been shown to expand CD19-specific CAR-T cells [27–32]. Compared to the method of T cell expansion with γ-irradiated feeder cells, expansion with CD19-expressing aAPCs was able to proliferate T cells with increased CAR expression and increased cytolytic activity [27].

Signal 2: co-stimulatory molecule signal

Engagement between TCR and p-MHC complexes is necessary, but not sufficient, for the activation of T cells [33, 34]. In fact, triggering the TCR alone usually leads to limited expansion, followed by unresponsiveness after reencountering antigen. To effectively activate T cells, co-stimulatory molecule signals have to be provided to T cells. Co-stimulatory signaling plays a critical role in modulating T-cell activation, differentiation, effector function, and survival. Thus, numerous co-stimulatory molecules (such as CD28, 4-1BB, CD83 and adhesion molecules) can be applied to the aAPC for enhancing the immunotherapy. The next section reviews the biological functions of different co-stimulatory signals and the effects of co-stimulatory molecular signals expressed on aAPCs for adoptive T cells.

Co-stimulatory signals mediated by CD28

Multiple biological functions, including T cell expansion, IL-2 secretion, and Th1 differentiation, were mediated by the interaction between CD28 and corresponding receptor [35]. Therefore, most aAPCs express the related receptor CD80(B7-1) or CD86(B7-2) of CD28 [20, 36–38]. Data suggest that aAPCs expressing CD80 were crucial to sustain the proliferation and re-stimulation of CD19-specific CAR-T cells [39]. Intercellular cell adhesion molecule-1 (ICAM-1) provides synergistic signals via LFA-1 molecules expressed on T cells. Preclinical evidence indicates that ICAM-1 expression results in weak antigen-specific CTL stimulation and limited tumour protection [40]. In addition, ICAM-1 has extensively documented its synergistic effect with CD28. A study co-transfected B7-1 and ICAM-1 into Drosophila cells to produce the novel aAPCs that trigger sustained T cell proliferation, cytokine secretion and specific cytotoxicity [41]. A research team modified a mouse fibroblasts-based aAPC that expressed an HLA-peptide complex along with B7-1, ICAM-1, and LFA-3. The strategy elicited strong stimulation and consistent proliferation of CTLs [42].

Co-stimulatory signals mediated by 4-1BB

4-1BB is an inducible receptor derived from the tumour necrosis factor (TNF) receptor superfamily [43]. The ligand named 4-1BBL, expressed on a fraction of DCs constitutively, is inducible in macrophages, B cells, and T cells. In the presence of TCR engagement, 4-1BBL or agonist monoclonal antibodies signal through 4-1BB to trigger T cell expansion, produce cytokines, and prevent activation-induced cell death (AICD) [44, 45] To determine which co-stimulatory molecules could promote the expansion of CD8+ T cells with effective functions, a series of different aAPCs were designed to improve adoptive T cells [38]. In contrast to aAPC expressing CD80 alone, aAPC expressing 4-1BBL alone can maintain a longer proliferation of CD8+ T cells. In addition, another research demonstrated that the addition of 4-1BBL can maintain the TCR diversity of T cells and reduce apoptosis of CD8+ T cells [46]. It is worth noting that the effect of aAPCs co-expressing CD80 and 4-1BBL is better than that of APCs expressing only one agonist molecule [38]. The 4-1BB signal is essential for the amplification of CD8+ T cells, but the long-term growth of CD4+ T cells does not depend on the 4-1BBL signal [47]. Of note, compared to aAPC expressing 4-1BBL or B7-1 alone, aAPC co-expressing 4-1BBL and B7-1 enhanced the effector CTL anti-tumour response [48].

Co-stimulatory signals mediated by CD83

Human CD83 is the signature of mature DCs, and also expresses on activated B cells and T cells [49]. The downregulation of CD83 in DCs results in a reduction in their capacity to induce T cell proliferation. Furthermore, DCs downregulating CD83 induce a reduction in interferon (IFN-γ) secretion by activated T cells. CD83 ligands have been shown to induce the long-term expansion of CD8+ T cells, with a preferential enrichment of antigen specificity [20]. Furthermore, CD83 has been demonstrated to be crucial for the longevity of B cells and CD4+ T cells [50]. The precise impact of CD83 on aAPC or T cells remains to be elucidated, and some studies indicate that CD83 may act in a synergistic manner with CD28 and/or 4-1BB signal. In general, CD83 is responsible for the preferential enrichment and long-term amplification of antigen-specific CTLs, while this process also requires the participation of CD80 [20, 22]. The co-expression of aAPC with CD80 and CD83 also inhibited cell apoptosis in CTL compared to aAPC expressing CD80 only.

Adhesion molecules

The stable formation of immune synapses (IS) is one of the key factors in T cell activation. Adhesion molecules play a pivotal role in establishing a stable IS. As a crucial adhesion molecule, the ICAM-1 is also frequently used in the aAPC system. The importance of ICAM-1 and its synergy with CD28 has been widely demonstrated [41, 42]. Some studies suggest that the expression of additional co-stimulatory and/or adhesion molecules on aAPC may further enhance the capacity to promote antigen-specific T cell population proliferation. These adhesion molecules are highly expressed on DCs and can induce naive T lymphocytes. The major roles of B7-1, ICAM-1, and LFA-3 in co-stimulating CTLs have been documented [51, 52]. Drosophila cells transducing ICAM-1 and B7-1 transform into highly effective aAPCs, inducing robust proliferative and cytokine production. [41]

Overall, CD28 co-stimulatory signals were able to induce sustained T cell proliferation, cytokine secretion, and specific cytotoxicity. The 4-1BB co-stimulatory signaling is important for sustained T cell proliferation. In addition, CD83 co-stimulatory signals act in concert with other co-stimulatory molecules to inhibit the exhaustion of T cells. Adhesion molecules can also synergize with other co-stimulatory signals to promote the formation of IS and further promote T cell proliferation and cytokine secretion. The mechanism of synergistic interaction between co-stimulatory molecules remains unclear. At present, it has not been demonstrated whether the interaction of co-stimulatory molecules activates two discrete signaling pathways or initiates a unique signal transduction pathway. Further investigations are needed to demonstrate the importance of the expression of different co-stimulatory ligands in aAPC for the induction of different functions in T cells.

Signal 3: aAPCs armed with diverse cytokines

Cytokines are essential for promoting T-cell proliferation, survival, and anti-tumour function [16, 53]. IL-2 is a key cytokine regulating the innate and adoptive immune system. IL-2 has the ability to mediate and regulate multiple biological events, particularly in T cell proliferation, differentiation, and development [54]. IL-2 can stimulate natural killer (NK) cell proliferation and amplify cytolytic activity [55]. Antibody production and proliferation of B cells can also be induced by IL-2 [56]. However, IL-2 exposure can cause AICD [57], and the production of immunosuppressive Treg cells. Given the important role of IL-2 for immune cells, the vast majority of current protocols utilizing K562-aAPC as a T cell stimulator require the incorporation of IL-2 into the culture.

In addition to IL-2, another two γc family cytokines (IL-15 and IL-21), also play important roles in T cell growth and development. IL-15 has a significant effect on memory cells’ proliferation and anti-apoptosis [58]. IL-21 can stimulate cell proliferation, regulate gene expression and the differentiation of Th1 or Th2 cell [59, 60]. Both IL-15 and IL-21 are involved in maintaining and expanding memory CD8+ T cells, NK cells, NKT cells [61]. In the presence of exogenous IL-2, NIH-3T3 aAPCs have difficulty maintaining sustained T cell expansion [39]. The sustained proliferation of tumour-specific T cells can be maintained in the presence of IL-15, allowing the preparation of T cells on a clinical-use scale. The therapeutic potential of T cells expanded in the presence of IL-2 or IL-15 was also compared. The study has reported that T cells expanded in the presence of IL-15 had greater anti-tumour activity and eradicated established tumours in animal models. Recently, we noted that aAPC expressing tumour antigens can increase CAR-T cell-specific proliferation; however, persistent tumour antigen stimulation may result in faster CAR-T exhaustion [62]. The presence of exogenous IL-2, IL-9, and IL-21 alleviated the dysfunction of CAR-T cells and further promoted anti-solid tumour capacity of CAR-T cells.

It is also feasible to genetically design aAPCs to produce or express cytokines in a membrane-bound form. Clone#4 (CD19, CD64, CD86, 4-1BBL, and membrane junctions co-expressed on K562)was created to support the specific amplification of CD19-specific CAR-T cells. However, it also requires the presence of the external cytokines IL-2 and IL-21 [32]. aAPCs with membrane-bound cytokines are largely employed to stimulate NK cell proliferation. Common γc-chain cytokines such as IL-2, IL-15, and IL-21 play a significant role in the activation, maturation, and proliferation of NK cells. aAPCs expressing mbIL-21, unlike mbIL-15, supported the proliferation of NK cells and showed no evidence of senescence after up to 6 weeks of incubation [63–65]. The phenotypic and cytotoxicity of mbIL-21-amplified NK cells were comparable to those of mbIL-15-amplified cells. NK cells amplified with mbIL-21 have shown considerable cytotoxicity against all tumour cell lines. Additionally, NK cells after culture increased antibody-dependent cell-mediated cytotoxicity (ADCC), while maintaining the responsiveness to inhibitory killer cell immunoglobulin-like receptors (KIRs).

The impact of a single cytokine on adoptive cells has been extensively researched, yet the influence of distinct combinations of cytokines on the phenotype of adoptive cells remains uncertain. Furthermore, cell-based APCs can be employed as an efficacious instrument to investigate the impact of disparate cytokines on adoptive cells.

One of the key processes in achieving clinical efficacy of tumour-specific T-cell immunotherapy is that the APC presented signals from tumour cells to T cells, which activates tumour-specific T cells and enables them to lyse cancer cells. Understanding how different signals affect T cell fate helps researchers apply these signals to the preparation of aAPC, with a view to developing adoptive T cells with a more powerful anti-tumour function.

Fig. 1 Signals on aAPC to meet the therapeutic needs of adoptive T cells. A MHC molecules and target surface antigens provide specific proliferative signals for T cells. B Co-stimulatory molecules are an essential signal for T cell proliferation and differentiation. C Different exogenous cytokines and membrane-bound cytokines promote the proliferation and differentiation of immune cells with different functions. MHC major histocompatibility complex

Advantages and limitations of different aAPCs

Several studies have demonstrated that the utilization of autologous APCs in ACT contributes to favorable clinical outcomes and minor adverse side effects [66, 67]. Those results highlight the promise of APCs in adoptive immunotherapy. Unfortunately, the applications of natural APCs over the years have also encountered some significant limitations (Table 1). The isolation and stimulation of autologous APCs in vitro is a time-consuming and costly process [68, 69]. Moreover, the quality of autologous APCs generated in vitro is uneven. Consequently, investigators have generated various types of aAPCs to better expand T cells. We review these aAPCs directly below. Artificial antigen-presenting systems encompass both cell-based (Fig. 2A) and acellular systems (Fig. 2B). aAPC prepared using distinct material compositions exhibits distinctive advantages and limitations. The following section will present the distinguishing characteristics of the various aAPCs. We contend that this can serve as a guide for researchers in applying aAPC in ACT.

Fig. 2 Classification, advantages and limitations of aAPC. aAPC is mainly divided into cell-based aAPC and non-cellular aAPC. A According to its different cytoskeleton, cell-based aAPC is classified into: Drosophila melanogaster cell, mouse fibroblast NIH/3T3 and human erythroleukemia cell K562-based aAPC. B Different non-cellular aAPCs, and their advantages and limitations

Cell-based aAPC

Specific cells must satisfy several requirements to be candidates (backbone cells), which will be used in the construction of the universal aAPCs. First, the induction of allospecific T cells by backbone cells should be absent or minimal if any does occur. Therefore, the backbone cells do not express any HLA class I or II molecules. Second, the candidate cells must be readily amenable to genetic manipulation and the expression of the manipulated genes must be stable. Third, it would be preferable for the backbone cell line to have a documented history of safe use in humans.

Drosophila melanogaster cells

One of the earliest cell-based aAPC systems employed Drosophila cells. Because Drosophila melanogaster cells do not possess antigen-processing-related transporters, they cannot present endogenous peptides to HLA class I molecules. Drosophila cells are unable to process endogenous antigens and do not induce allogeneic responses. Consequently, Drosophila melanogaster cells are considered to offer an outstanding exogenous peptide epitope [41, 70, 71]. Drosophila-derived aAPCs were transduced with HLA-A*0201 and pulsed with tyrosinase peptides to expand tyrosinase-specific CD8+ T cells, which were infused into melanoma patients subsequently [72]. Washing the CTL product prior to refusion effectively eliminated aAPC, and no adverse effects associated with insect cells were observed in any of the patients. However, this limits their applicability in studies requiring antigen processing. The application of a Drosophila melanogaster cell-derived aAPC presents a significant flaw. The aAPC of Drosophila melanogaster cannot survive at 37 ℃ without the aid of peripheral blood monoculear cell (PBMC) feeder cells. [71] Scientists have therefore investigated other cells as alternative aAPC scaffolds.

Mouse fibroblast NIH/3T3

In contrast to Drosophila aAPC, NIH/3T3 cells exhibit the capacity for endogenous antigen processing. This has been observed to stimulate the CD8+ T cells to respond to exogenous antigens that have been loaded and transfected [73]. NIH/3T3 cells are commonly employed for the activation of mouse and human CTL because of multiple characteristics. The properties include facile expansion, sustained gene expression and antigen processing [40, 42, 74]. Mouse fibroblasts have the extra advantage of being more stable and easier to manipulate in culture than Drosophila cells. Furthermore, the reduced ability of fibroblasts to digest peptides and load them onto MHC molecules in comparison to professional APCs may promote the expression of certain HLA-polypeptide complexes by lowering the simultaneous expression of unrelated peptides [75, 76]. To illustrate, NIH/3T3 cells transduced to express CD80, 4-1BBL, and the prostate-specific membrane antigen (PSMA) were shown to effectively expand PSMA+ CAR-T cells [77]. The resultant T cells were observed to be effective in the treatment of PSMA-positive tumours in a humanized mouse model.

Human erythroleukemia cell K562

K562 serves as the scaffold for the cell-based aAPC due to several reasons [22]. First, K562 cells lack HLA expression, which prevents allogenic responses. At the same time, HLA-deficient K562 cells do not activate KIRs. Therefore, K562-derived aAPC are ideal for expanding NK cells [78]. Second, the cells also contain adhesion molecules that enhance T-cell–aAPC interactions. The fact that K562 cells do not secrete pro-inflammatory cytokines such as IL-12 or type I IFN may facilitate selective expansion of central memory T cells. Importantly, previous studies have demonstrated that K562 can stably express a wide range of molecules on the surface, suggesting that K562 is suitable for gene transduction [20, 28, 38]. As a consequence, K562-based aAPCs are currently the most widely utilized in cell therapies. K562 aAPCs genetically modified to express CD64, CD86 and CD137L were demonstrated to facilitate the expansion of NKG2D CAR-T cells from small volumes of peripheral blood samples [37]. CAR-T cells expanded with these aAPCs are capable of meeting the requirement for multiple transfusions in the treatment of solid tumours [37]. Stimulation of CD8+ T cells with peptide-pulsed aAPC produces a considerable number of functional CTLs [22]. These CTLs are capable of recognizing a wide range of tumour antigen. And CTLs expanding with aAPC are capable of lysing a variety of melanoma tumour lines that naturally express target melanoma antigens.

Acellular synthetic aAPCs

Lipid-based aAPC and exosome-based aAPC

The fluidity and flexibility of the cell membrane facilitate the formation of immune synapses between APCs and T cells, thereby promoting T cell activation. In order to emulate the natural interactions between APCs and T cells, lipid-based aAPCs have been developed [11]. The preparation of lipid-based aAPC is a relatively convenient process, and it has been extensively employed for the expansion of clonal T cells and antigen-specific T lymphocytes [79, 80]. Nevertheless, the most notable drawback associated with lipid-based aAPC is instability, which may result in inadequate activation of T cells [81]. In order to improve the stability of lipid-based aAPC, lipid bilayer aAPC with solid particles as scaffolds, also known as a supported lipid bilayer, was developed [82, 83]. For example, aAPC prepared by encapsulating natural cell membranes on silica microbeads and latex microbeads can effectively stimulate T cell proliferation [84]. Exosomes are extracellular vesicles that can be produced by tumour cells or other types of cells [85–87]. They have been demonstrated to stimulate immune responses in vivo. Tumour cell-derived exosomes also necessitate the involvement of cells (such as DCs) for antigen presentation [85], whereas DC-derived exosomes do not. Exosome-like vesicles secreted by the Drosophila melanogaster aAPCs have been demonstrated to stimulate the IL-2 and IFN-γ production of mouse CD8+ T cells in vitro [88]. Exosomes retain the advantages of cell membrane scaffolding as cellular nucleus-less structures. Nevertheless, the potential of exosomes to support ex vivo T-cell expansion remains to be elucidated.

Polymeric aAPC

Polymers such as polystyrene beads and lactic-co-glycolic acid (PLGA) have also been employed in the generation of aAPCs [9, 89, 90]. Polymeric aAPCs not only immobilize molecules such as pMHC, CD3, CD28 on the surface, but also slowly release soluble cytokines [91]. Compared to the traditional method of adding exogenous cytokines, the slow release strategy has been proven to promote T cell proliferation more effectively [91]. Three signals essential for activating T cells are integrated into a single polymeric aAPC, which facilitates the rapid expansion of clonal T cells. The structural malleability of polymeric aAPCs is another advantage. By replacing round aAPCs with oval ones, the contact area between aAPCs and T cells can be increased [92]. The oval-shaped PLGA aAPC has been demonstrated to promote stronger T-cell proliferation in vitro and to stimulate stronger immune response in mice [93]. Nevertheless, a significant limitation of polymeric aAPC is its surface rigidity.

Inorganic aAPC

Inorganic aAPC Inorganic aAPC involves carbon nanotubes [94] and magnetic particles [95]. Magnetic beads were developed by Levine et al. to maximize the expansion of T cells in vitro [15]. Anti-CD3/CD28 dynabeads are the most widely used aAPCs for ACT. The product has been approved by the US Food and Drug Administration (FDA) for the activation and expansion of T cells [95, 96]. Carbon nanotubes are nanomaterials with a large surface area and can locally adsorb high concentrations of stimulatory ligands [97]. When anti-CD3/CD28 antibodies are adsorbed on carbon nanotubes, the antibodies aggregate and form antibody clusters in the concave region on the surface to promote T-cell activation [98]. However their application in vivo T-cell activation has been limited due to their cytotoxicity and poor biocompatibility [99]. It is necessary to remove the aAPC completely prior to infusion of T-cells, which presents a significant challenge for the quality control of adoptive T-cells.

Table 1 Advantages and limitations of different aAPCs

Types of aAPC	Advantages	Limitations	
Acellular aAPC			
 Lipid-based aAPC	Fluidity and flexibility of the cell membrane

Easy preparation fluid membrane, good biosafety profile

	Unstable Low T cell activation	
 Exosome-based aAPC	Fluidity and flexibility of the cell membrane, good biosafety profile	Preparation is difficult	
 Polymeric aAPC	Structural formability	Rigid surface	
 Inorganic aAPC	Carbon nanotubes: high surface area, ligand pre-clustering

Dynabeads: Easy preparation, easy enrichment and separation, controlled by magnetic field, widely used

	Non-biodegradable	
Cell-based aAPC			
 K562 cell-based aAPC	Almost no expression of the HLA molecules, expressing adhesion molecules promotes immune synapse formation, ease of generation/handling	Risk of tumourigenesis	
 NIH/3T3 cell-based aAPC	Ease of generation/rapid expansion of the aAPC, stable and ease of manipulation in culture	Heterogenetic, the lower ability of fibroblasts to process peptides and load them onto MHC molecules compared to specialized APC	
 Drosophila melanogaster cells-based aAPC	Does not induce a heterogeneous response

Lack antigen processing related transporters

	Self-elimination at 37 °C, peptide pulsing required

Need extra feeder cell

	
Autologous APC	 Minor adverse side effects	Time-consuming and expensive

Equality of ex vivo-generated autologous APC can be variable

	

Cell-based aAPC system in ACT

The complete cellular structure and the adhesion molecules expression of K562-based aAPC were able to promote the formation of the immune synapse. These properties were more effective in mimicking the physiological interaction between T cells and APC [22]. The interactions are critical for aAPC to signal to T cells [12]. The applications of acellular aAPCs have recently been extensively reviewed [81, 100, 101], and this review will focus on the use of cell-based aAPCs in ACT.

Application of cell-based aAPC in CAR-T cell therapy

The preclinical or clinical amplification of CAR-T cells was mainly stimulated with microbeads coated with anti-CD3/CD28 antibodies. One limitation of this amplification method is that the expansion of T cells is not CAR-specific. The researchers compared anti-CD3/CD28 monoclonal antibody-coated beads with aAPC expressing mOKT3, CD80, and CD83 molecules [102]. The study discovered that brief stimulation of cell-based aAPCs, rather than long-term beaded stimulation, resulted in greater CD8+ T cell expansion. Transiently stimulated CD8+ T cells maintain the stem-like memory phenotype and secrete multiple cytokines more efficiently than long-stimulated T cells. Therefore, several groups have used aAPCs expressing CAR-target antigens to proliferate CAR-specific T cells [27–29, 37]. According to a research, aAPC increased the cytolytic potential of CAR-T cells by encouraging the selective proliferation of CAR+ T cells, even if the expansion rate was somewhat slower than that of CAR-T cells expanded using allogeneic feeder cells [27]. CD19+ 4-1BBL+ MICA+-K562 amplified CAR-T cells had not only strong selective amplification but also higher cytolytic activity [28]. Some studies showed that when stimulated by the supernatants of T cells activated by IFN- γ, TNF- α, CD3/CD28, K562 may upregulate the expression of MHC class I molecules [103, 104]. MHC class I negative K562 cells were generated by destroying the B2M motif in K562 cells using CRISPR/Cas9 technology [36]. These aAPCs could attenuate allogeneic immune responses while promoting robust antigen-dependent and CD19-specific CAR-T cell proliferation. A research team is generating clinical-grade CAR+ T cells with K562-based aAPC (clone#4). Clone#4-expanded CAR-T cells can be used to treat B-lineage lymphoid malignancies and B cell chronic lymphocytic leukemia [32, 105]. Monocyte contamination of the starting T cell source suppresses microbead-based CAR-T amplification, and in some cases causes production failure [106, 107]. To address this issue, aAPC was prepared from K562 low-density lipoprotein receptor (LDLR) knockdown cells for the activation and expansion of T cells [108]. The LDLR-knockdown aAPC amplified CAR-T cells more effectively than magnetic beads or inactivated PBMC. The survival and anti-tumour efficacy did not differ significantly between this aAPC and magnetic bead-expanded CD19+ CAR-T cells in vivo. The NKG2D ligand is expressed endogenously on K562 and increases upon irradiation. Tay et al. demonstrated how to generate clinically relevant NKG2D CAR-T cells by aAPC cells co-expressing CD64, CD86, and 4-1BBL [37]. This aAPC amplification produced the final cell therapeutic product with 89.2% ±10.2% NKG2D CAR+ T cells. The expression of exhaustion markers TIM-3 and LAG-3 on T cells decreased with culture time, but did not alter antitumour efficacy of CAR-T cells. Heparin II binding domain (HBD) is significant in helper gene transduction [109, 110]. In order to promote CAR gene transduction, K562 cells were co-transduced HBD, anti-CD3, and anti-CD28 scFv and 4-1BBL [111]. This aAPC supported efficient gene transduction and CAR-T cell expansion, and fewer CAR-T cells were exhausted than beads-amplified ones.

The majority applications of aAPC in CAR-T cell therapy are for hematological tumour. Recently, we proposed a new strategy in aAPC to treat solid tumours [62]. This involves co-infusion of CAR-T cells with aAPCs that express chemokines and costimulatory ligands. This approach enhances the antitumour effect in mice. We also found that a cytokine cocktail (IL-2, IL-9 and IL-21) can effectively amplify the anti-tumour effect. Conceptually, aAPC system is an appealing platform for taking advantage of the simple genetic modification of cells such as K562. aAPC can thus improve T cell function and overcome several challenges encountered by CAR-T in the treatment of solid tumours.

Application of cell-based aAPC in TIL therapy

Tumour infiltrating lymphocyte (TIL) adoptive therapy are to collect T lymphocytes from the tumour site, which is expanded by in vitro culture, and then infused into patients [112]. However, the in vitro expansion of autologous TIL requires a large number of allogeneic PBMC cells as feeder cells, which is time-consuming and costly. Therefore, aAPC as an off-the-shelf “feeder cells” is also one of the effective means for rapid expansion of TIL [113, 114]. Co-expressed a membrane-bound monoclonal antibody (anti-CD3 antibody) and CD80 and CD83 on K562 cells to generate a novel aAPC [115]. This aAPCs efficiently amplified not only CD3+ peripheral T lymphocytes but also T lymphocytes recovered from ascites in breast and ovarian cancer patients. The aAPC platform was used to rapidly amplify tumour-infiltrating lymphocytes from primary tumour specimens, based on the Carl H June designed aAPC-K32, and further co-transfection with co-stimulatory molecule 4-1BBL and allowing it to secrete IL-2, IL-15, or IL-21 cytokines [116]. These amplified TIL are more central memory and effector memory phenotypes, and also highly express molecules such as CD27 and CD28 that are associated with the survival and persistence of T cells in vivo. Treg cells do not respond to stimulation of this aAPC, and thus this aAPC is believed to efficiently amplify functional TIL without causing immunosuppression [117].

Application of cell-based aAPC in CTL therapy

Antigen-specific cytotoxic T lymphocytes are also one of the promising immunotherapies for cancer treatment [118]. However, existing approaches for increasing CTL can take months or longer, posing a substantial constraint in cancer treatment. Many studies have demonstrated that aAPC can rapidly amplify antigen-specific CTL. Drosophila cells transfected with MHC-class I molecules are able to induce autologous spleen cells to respond to tumour-specific peptides in vitro. And CTL produced by this aAPC system was able to inhibit mouse P815 mastocytoma growth [119]. Another institution used K562-CD32-4-1BBL cells coated with anti-CD3/28 antibodies as aAPC to induce long-term growth of antigen-specific CTL. They found that expressing 4-1BBL on K562 helped reduce the apoptosis of CD8+ T cells, increasing T cell persistence and cytolytic capacity [46]. Several studies have demonstrated aAPC generated by co-expression of HLA-A2, CD80 and CD83 on K562 cells can be used to amplify long-lasting antigen-specific CTLs. The presence of CD83 maintains low expression of the depletion molecules LAG-3, PD-1, CTLA-4 and TIM-3 on CD8+ T cells, which favors the enrichment of antigen-specific T cells. These enriched antigen-specific CD8+ T cells have potent lysis effects on a wide range of melanoma cell [20, 22]. Based on their experience in preparing aAPCs to amplify CD8+ T cells, this team also generated a novel aAPC to stimulate HLA-DR-restricted antigen-specific CD4+ T cells. K562 has been engineered to express HLA-DR as a single HLA allele in addition to invariant chain (Ii), HLA-DM, CD80 and CD83 [26]. These results suggest that K562-based aAPC may serve as a translational platform for the generation of both antigen-specific CD8+ CTL and CD4+ T cells.

Application of cell-based aAPC in NK cell therapy

NK are innate lymphocytes that can identify and remove virus-infected and tumour cells. NK can recognize targets without HLA restriction, making them appealing candidates for universal cellular immunotherapy. K562 cells are widely used in the production of NK cells because they do not express HLA molecules and do not factor the KIRs [78, 120, 121]. Membrane-bound IL-15 and 4-1BBL co-expressed on K562 cells acted synergistically to expand peripheral blood NK cells without concomitant growth of T lymphocytes [63]. Notably, aAPC expanded CAR-NK also showed significant anti-leukemia activity [64]. The K562-aAPC, which co-express CD64, CD86, 4-1 BBL, a truncated CD19 molecule and membrane-bound IL-21, were employed to facilitate NK cell proliferation [65]. This aAPC allows the generation of large numbers of activated NK cells from PBMC of children with high-risk neuroblastoma. In vitro, these NK cells are highly cytotoxic to multidrug-sensitive and resistant neuroblastoma cell lines, either alone or in combination with mAb ch14.18, and secrete a variety of antitumour cytokines and chemokines when mediating ADCC.

Human invariant natural killer T (iNKT) cells express invariant TCR Vα24, which pairs with TCR Vβ11 and recognizes glycolipids on monotype CD1d. Thus, tumour-specific iNKT cells can attack CD1d+ tumour cells, such as leukemia and lymphoma, without HLA restriction [122, 123]. iNKT cells were amplified using aAPCs produced by transferring CD1d, CD80, and CD83 into K562 cells [124]. These aAPCs were used to pulse synthetic ligands, such as α-Galactosyl ceramide, in order to amplify highly polyclonal iNKT cells containing various CDR3β sequences. The iNKT cells that have been amplified secrete IFN-γ and/or IL-4 in a CD1d-dependent manner. Furthermore, their subpopulations recognize endogenous ligands presented by CD1d and are self-reactive.

Clinical research on the cell-based aAPC

Currently, only aAPCs based on Drosophila and K562 can be used under GMP conditions, and their safety and tolerability have been demonstrated in a number of clinical trials (Table 2) [125, 126]. To study the distribution and toxicity of CTLs against a single melanoma epitope. Drosophila cells transduced with HLA-A2.1, CD80, and ICAM-1 were used for priming, followed by two rounds of immunization with mononuclear cells as antigen-presenting cells [72]. In this trial, partial responses were observed following CTLs therapy. PCR amplification used to detect Drosophila melanogaster cells prior to returning the cells to the patient showed that the washing procedure effectively removed aAPCs.

K562 cell-based aAPCs are more widely used in clinical trials for ACT. aAPC co-expressing CD64 and 4-1BBL on K562 were used to amplify CTL for Phase I melanoma clinical study (NCT01369875). Another clinical study on melanoma was conducted by Naoto Hirano’s team (NCT00512889), based on preclinical study data [22], they generated an aAPC-A2 clone33 co-expressing HLA class I, CD80, and CD83 for amplification of HLA Class I restricted T cells. In the previous stage, they amplified TIL cells with melanoma-associated antigen MART1 positive using aAPC-A2 clone33, and the amplified TIL cells have achieved good results in terms of in vitro proliferation and specific anti-tumour effects. At present, no response has been seen in melanoma patients treated by these two clinical treatments, and those studies have been closed. The Baylor College of Medicine team has designed a clinical-grade aAPC: transduction of CD32, CD80, CD86, CD83 and the co-stimulatory molecule 4-1BBL on K562 to amplify EBV-specific T cells for Phase I treatment of EBV-specific lymphoma (NCT01555892). This approach offers the potential to replace the use of autologous EBV-transformed B cells as APCs. This provides a simpler and more convenient method of adopting T-cell therapy for EBV, VZV, vaccinia virus, cytomegalovirus, and adenovirus-associated diseases. Cooper’s group prepared clinical grade clone # 4 for the generation of clinically relevant functional CD19-specific CAR-T cells. Clinical studies using this aAPC have undergone successful FDA review and three clinical studies have been conducted for the treatment CD19+ hematologic malignancies (NCT01497184, NCT01362452, NCT01653717).

Several research groups are using K562-based aAPCs to generate large numbers of NK cells for the treatment of hematological cancers. The Center for Cell and Gene Therapy at Baylor College of Medicine manufactured aAPC, K562-mbIL15-4-1BBL, which was first reported by Campana and colleagues at St. Jude Children’s Research Hospital [64, 127]. NK cells amplified by the K562-mbIL15-4-1BBL were used to treat recurrent high-risk multiple myeloma in asymptomatic but high-risk patients or in combination with bortezomib. Clinical-grade aAPC (Clone #9) expressing CD64, CD86, CD19, CD86, 4-1BBL, and membrane-bound IL-21 was used for NK cell amplification in another set of NK studies at MD Anderson. The MD Anderson team is focusing on using NK cells to treat CLL, multiple myeloma, and myeloid leukemia 5–8 days before stem cell infusion. As previously stated, the phenotype and cytotoxicity of NK cells amplified with aAPC (Clone #9) were comparable to that of aAPC expressing IL-15 rather than IL-21, but with superior cytokine secretion and proliferation [128, 129]. Unfortunately, there is no evidence that aAPC produces NK cells with superior transplant or antitumour function in vivo.

Treg cell expansion with aAPC has also been used to prevent graft-versus-host-reaction (GVHD). Blazar and colleagues used lentivirus gene transfer to create clinical-grade KT64/86, K562 cells that express CD86 and CD64 [130]. In the presence of IL-2 and rapamycin, KT64/86 cells were loaded with anti-CD3 monoclonal antibodies and used to amplify purified, polyclonal, human natural Treg cells. KT64/86 amplified natural Treg cells were shown to be effective in alleviating GVHD in a xenogeneic model. These findings support the ultimate goal of generating a library of Tregs for off-the-shelf therapies to prevent and treat GVHD and transplant rejection using KT64/86 from multiple HLA donor Treg cells. Their current study (NCT00602693) involved + 1 day after cord blood stem cell transplantation. In this study, aAPC-generated Treg cells were given to a group of patients who were compared to a previous cohort of patients who had previously received CD3/CD28 beaded dilated Treg cells under the same regimen.

Taken together, cell-based aAPC can be used as a reliable and safe material for the expansion of adoptive cells for the treatment of tumours and/or GVHD.

Table 2 Clinical application of cell-based aAPC in ACT

Cells	Transduced molecules	Target cell for expansion	Clinical trials phase and status	Target disease	
Drosophila cell	HLA-A2.1, CD80 and CD54	CD8+ CTL	Phase I

Status: completed

	Tyrosinase-positive melanomas	
NIH/3T3	N/A	
K562	aAPC-A2, clone 33: HLA class I, CD80, CD83	Autologous aAPC-generated MART1+ T cells	NCT00512889, phase I

Status: completed

	Melanoma (Skin)	
7F11ECCE: CD64, 4-1BBL	TIL	NCT01369875, phase II

Status: terminated (premature closure. protocol did not meet its primary objective.)

	Metastatic melanoma

Skin cancer

	
K562cs: CD32, CD80, CD83 CD86, 4-1BBL	EBV-specific T cell	NCT01555892, phase I

Status: recruiting

	EBV-positive lymphoma: Hodgkin’s disease, non-Hodgkin’s lymphoma, lymphoproliferative disease, lymphoma	
aAPC (clone #4): CD64, CD86, 4-1BBL, truncated CD19, mbIL-15	Autologous CD19-specific CAR-T cells	NCT00968760, phase I

Status: completed

NCT01497184, phase I

Status: completed

NCT01362452, phase I

Status: completed

NCT01653717, phase I

Status: completed

	B-lineage lymphoid malignancies

After umbilical cord SCT

B-lineage lymphoid malignancies

After auto SCT

B-lineage lymphoid malignancies

After allo-SCT

B-cell chronic lymphocytic leukemia

	
4-1BBL, mbIL-15	Autologous NK cells	NCT01884688

Phase I

Status: completed

	Asymptomatic multiple myeloma	
4-1BBL, mbIL-15	Autologous NK cells plus bortezomib	NCT01313897

Phase II

Status: completed

	Relapsed high risk multiple myeloma	
aAPC (clone #9): CD64, CD86, 4-1BBL, truncated CD19, mbIL-21	Autologous NK cells	NCT01729091

Phase I

Status: unknown

	B-cell chronic lymphocytic leukemia undergoing umbilical cord SCT, multiple myeloma undergoing

umbilical cord SCT, and myeloid leukemia undergoing SCT

	
KT64/86: CD64, CD86	Natural Treg from umbilical cord cells	NCT00602693

Phase I

Status: completed

	Advanced hematologic malignancies with umbilical cord SCT	
CTL cytolytic T lymphocytes cells, TIL tumour infiltrating lymphocytes, CAR chimeric antigen receptor, NK natural killer, SCT stem cell transplantation

Conclusions

Cell-based aAPC is an appealing material for in vitro cell expansion in ACT. However, the application of cellular reagents has major limitations, including the possibility of contamination, immunogenicity, and tumourigenicity. To address contamination during the preparation of clinical-grade aAPCs, a standard preparation code and strict release criteria can be established. The risk of contamination can include culturing cells in culture isolator. Rigorous testing for viruses, mycoplasmas and bacteria before using aAPC-expanded T cells or NK cells is also essential [32]. Using xenogeneic NIH/3T3 cells or Drosophila melanogaster cells as aAPCs has the benefit of being genetically edited to express only one engineered HLA molecule, thereby avoiding alloreactivity. Studies have shown that NIH/3T3 cells rarely activate human T cells, implying that significant alloreactivity is less likely to occur when using xenogeneic aAPC [42, 73]. The immunogenicity of xenogeneic cells cannot be avoided due to the presence of xenogeneic antigens. However, recent clinical studies have demonstrated that washing procedures can remove the insect antigens released by Drosophila melanogaster, which do not cause any issues [72]. Before using cell-based aAPCs, their proliferative potential was lost by irradiation, thus eliminating the risk of tumourigenicity [39]. There was no evidence that aAPC caused tumour formation or other adverse effects when T cells expanded with mouse fibroblast aAPC were reinfused into mice. Studies have shown that after 5 days of co-culture with T cells, neither flow cytometry nor RT-PCR could detect the remaining K562 cells. This meant that aAPC could be completely eliminated from the culture [115]. The safety of irradiated cells has also been demonstrated in a number of tumour vaccine clinical trials [126]. However, the clinical study of aAPC for ACT is still in the early stages, and more clinical data is required to support its safety.

Acellular systems are currently being used as an alternative to cellular aAPC. Various acellular aAPC systems, including beads, liposomes, and exosomes, have been developed [81]. However, contact and signaling between acellular aAPC and immune cells rely entirely on artificial modification. Cellular aAPCs have a primary advantage over acellular aAPCs in their ability to effectively simulate physiological interactions between T cells and APCs. These interactions are essential for aAPC signaling of T cells, particularly in terms of allowing the migration of molecules required to activate T cells [12]. Naturally expressed adhesion molecules on K562 cells, for example, aid in the formation of immune synapses between T cells and aAPC, which is absolutely essential for aAPC signaling of T cells. The signaling of acellular aAPC to T cells is also affected by the characteristics of the T cells themselves [81]. The most commonly used aAPC system is antibody-coated beads, which are simple but may have limited function due to their mechanical rigidity and limited ability to display different ligands. Liposome aAPC function is also influenced by its size and stability [11, 81].

The primary goal of aAPC development is to create an alternative system for providing effective activation and proliferation signals for in vitro adoptive cell culture. This is achieved by avoiding the difficult-to-isolate and preparing professional APCs. The properties of amplified T cells are not limited to cell number, phenotype, and in vitro lysis activity. The signals sent by aAPCs must be strong enough to stimulate proliferation but not strong enough to induce AICDs for terminal differentiation or high-affinity T cells. Developing appropriate aAPC for the production of adoptive cells with optimal function is a future research trend and challenge. Currently, cellular aAPC is primarily created through gene modification to express three signals required for T cell activation: the TCR-pMHC complex, co-stimulatory signaling, and cytokines [131]. In addition to signals that activate T cells, there are also inhibitory signals, such as apoptosis-inducing molecules, that deplete against antigen-specific T cells. One advantage of aAPCs is their ability to be genetically modified to express various co-stimulatory or inhibitory molecules, which is useful for analyzing different T cell responses and improving adoptive T cell function. Additionally, Schoenberger, S.P. et al. conducted a study on the requirements for antigen density and co-stimulatory molecules during direct CTL initiation with aAPC. Properly engineered aAPCs can efficiently expand adoptive cells without the risk of cross-reactions [40]. In summary, aAPC is not only an efficient method for expanding adoptive cells in vitro, but it also provides a good platform for elucidating the biological requirements of T cells with high therapeutic potency.

Author contributions

Jing Li: Conceptualization, Methodology, Writing – original draft, Writing – review & editing. Weilin Zhou: Drew the figures & review. Wei Wang: Provided valuable guidance and revised the paper. All authors have read and approved the article.

Funding

This work was supported by The International Cooperation Project of Sichuan Province (2021YFH0002), National Natural Science Foundation of China (81972878), the National Key Research and Development Program of China (2020YFC0860200) and Key Research and Development Program of Sichuan Province (2020YFS0008).

Data availability

Not applicable.

Declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Consent for publication

Not applicable.

Ethical approval

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jing Li, Weilin Zhou have contributed equally as first author.
==== Refs
References

1. Rosenberg SA Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med 1988 319 1676 1680 10.1056/nejm198812223192527 3264384
Rosenberg SA et al (1988) Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680. 10.1056/nejm1988122231925273264384 10.1056/nejm198812223192527
2. Dudley ME Rosenberg SA Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat Rev Cancer 2003 3 666 675 10.1038/nrc1167 12951585
Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675. 10.1038/nrc116712951585 10.1038/nrc1167
3. Rosenberg SA Restifo NP Adoptive cell transfer as personalized immunotherapy for human cancer Science (New York N Y) 2015 348 62 68 10.1126/science.aaa4967 25838374
Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York N Y) 348:62–68. 10.1126/science.aaa496725838374 10.1126/science.aaa4967
4. Das RK Vernau L Grupp SA Barrett DM Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers Cancer Discov 2019 9 492 499 10.1158/2159-8290.Cd-18-1314 30630850
Das RK, Vernau L, Grupp SA, Barrett DM (2019) Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov 9:492–499. 10.1158/2159-8290.Cd-18-131430630850 10.1158/2159-8290.Cd-18-1314
5. Singh N Perazzelli J Grupp SA Barrett DM Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies Sci Transl Med 2016 8 320ra323 10.1126/scitranslmed.aad5222
Singh N, Perazzelli J, Grupp SA, Barrett DM (2016) Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med 8:320ra323. 10.1126/scitranslmed.aad522210.1126/scitranslmed.aad5222
6. Fraietta JA Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Nat Med 2018 24 563 571 10.1038/s41591-018-0010-1 29713085
Fraietta JA et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563–571. 10.1038/s41591-018-0010-129713085 10.1038/s41591-018-0010-1
7. Tötterman TH Carlsson M Simonsson B Bengtsson M Nilsson K T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease Blood 1989 74 786 792 10.1182/blood.V74.2.786.786 2787679
Tötterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K (1989) T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 74:786–7922787679 10.1182/blood.V74.2.786.786
8. Maus MV Riley JL Kwok WW Nepom GT June CH HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4 + T cells Clin Immunol (Orlando Fla) 2003 106 16 22 10.1016/s1521-6616(02)00017-7
Maus MV, Riley JL, Kwok WW, Nepom GT, June CH (2003) HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4 + T cells. Clin Immunol (Orlando Fla) 106:16–22. 10.1016/s1521-6616(02)00017-710.1016/s1521-6616(02)00017-7
9. Oelke M Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells Nat Med 2003 9 619 624 10.1038/nm869 12704385
Oelke M et al (2003) Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9:619–624. 10.1038/nm86912704385 10.1038/nm869
10. Kim S Use of engineered exosomes expressing HLA and costimulatory molecules to generate antigen-specific CD8 + T cells for adoptive cell therapy J Immunother (Hagerstown Md: 1997) 2017 40 83 93 10.1097/cji.0000000000000151
Kim S et al (2017) Use of engineered exosomes expressing HLA and costimulatory molecules to generate antigen-specific CD8 + T cells for adoptive cell therapy. J Immunother (Hagerstown Md: 1997) 40:83–93. 10.1097/cji.000000000000015110.1097/cji.0000000000000151
11. Prakken B Artificial antigen-presenting cells as a tool to exploit the immune ‘synapse’ Nat Med 2000 6 1406 1410 10.1038/82231 11100129
Prakken B et al (2000) Artificial antigen-presenting cells as a tool to exploit the immune ‘synapse’. Nat Med 6:1406–1410. 10.1038/8223111100129 10.1038/82231
12. Rodríguez-Fernández JL Riol-Blanco L Delgado-Martín C What is an immunological synapse? Microbes Infect 2010 12 438 445 10.1016/j.micinf.2010.03.003 20227515
Rodríguez-Fernández JL, Riol-Blanco L, Delgado-Martín C (2010) What is an immunological synapse? Microbes Infect 12:438–445. 10.1016/j.micinf.2010.03.00320227515 10.1016/j.micinf.2010.03.003
13. O’Shea JJ, Johnston JA, Kehrl J, Koretzky G, Samelson LE (2001) Key molecules involved in receptor-mediated lymphocyte activation. Current protocols in immunology Chap. 11, Unit 11.19A, 10.1002/0471142735.im1109as44
14. Wen T Bukczynski J Watts TH 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function J Immunol (Baltimore Md: 1950) 2002 168 4897 4906 10.4049/jimmunol.168.10.4897
Wen T, Bukczynski J, Watts TH (2002) 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol (Baltimore Md: 1950) 168:4897–4906. 10.4049/jimmunol.168.10.489710.4049/jimmunol.168.10.4897
15. Levine BL Effects of CD28 costimulation on long-term proliferation of CD4 + T cells in the absence of exogenous feeder cells J Immunol (Baltimore, Md:1950) 1997 159 5921 5930 10.4049/jimmunol.159.12.5921
Levine BL et al (1997) Effects of CD28 costimulation on long-term proliferation of CD4 + T cells in the absence of exogenous feeder cells. J Immunol (Baltimore, Md:1950) 159:5921–593010.4049/jimmunol.159.12.5921
16. Schluns KS Lefrançois L Cytokine control of memory T-cell development and survival Nat Rev Immunol 2003 3 269 279 10.1038/nri1052 12669018
Schluns KS, Lefrançois L (2003) Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3:269–279. 10.1038/nri105212669018 10.1038/nri1052
17. Waldmann TA The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design Nat Rev Immunol 2006 6 595 601 10.1038/nri1901 16868550
Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595–601. 10.1038/nri190116868550 10.1038/nri1901
18. Bonehill A Heirman C Thielemans K Genetic approaches for the induction of a CD4 + T cell response in cancer immunotherapy J Gene Med 2005 7 686 695 10.1002/jgm.713 15693037
Bonehill A, Heirman C, Thielemans K (2005) Genetic approaches for the induction of a CD4 + T cell response in cancer immunotherapy. J Gene Med 7:686–695. 10.1002/jgm.71315693037 10.1002/jgm.713
19. Thibodeau J Bourgeois-Daigneault MC Lapointe R Targeting the MHC class II antigen presentation pathway in cancer immunotherapy Oncoimmunology 2012 1 908 916 10.4161/onci.21205 23162758
Thibodeau J, Bourgeois-Daigneault MC, Lapointe R (2012) Targeting the MHC class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 1:908–916. 10.4161/onci.2120523162758 10.4161/onci.21205
20. Hirano N Engagement of CD83 ligand induces prolonged expansion of CD8 + T cells and preferential enrichment for antigen specificity Blood 2006 107 1528 1536 10.1182/blood-2005-05-2073 16239433
Hirano N et al (2006) Engagement of CD83 ligand induces prolonged expansion of CD8 + T cells and preferential enrichment for antigen specificity. Blood 107:1528–1536. 10.1182/blood-2005-05-207316239433 10.1182/blood-2005-05-2073
21. Butler M Establishing CD8 + T cell immunity by adoptive transfer of autologous, IL-15 expanded, anti-tumour CTL with a central/effector memory phenotype can induce objective clinical responses Blood 2009 114 782 10.1182/blood.V114.22.782.782
Butler M et al (2009) Establishing CD8 + T cell immunity by adoptive transfer of autologous, IL-15 expanded, anti-tumour CTL with a central/effector memory phenotype can induce objective clinical responses. Blood 114:782. 10.1182/blood.V114.22.782.78210.1182/blood.V114.22.782.782
22. Butler MO Long-lived antitumour CD8 + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell Clin cancer Research: Official J Am Association Cancer Res 2007 13 1857 1867 10.1158/1078-0432.Ccr-06-1905
Butler MO et al (2007) Long-lived antitumour CD8 + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin cancer Research: Official J Am Association Cancer Res 13:1857–1867. 10.1158/1078-0432.Ccr-06-190510.1158/1078-0432.Ccr-06-1905
23. Kennedy R Celis E Multiple roles for CD4 + T cells in anti-tumour immune responses Immunol Rev 2008 222 129 144 10.1111/j.1600-065X.2008.00616.x 18363998
Kennedy R, Celis E (2008) Multiple roles for CD4 + T cells in anti-tumour immune responses. Immunol Rev 222:129–144. 10.1111/j.1600-065X.2008.00616.x18363998 10.1111/j.1600-065X.2008.00616.x
24. Tanaka M Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell Clin Cancer Res Off J Am Assoc Cancer Res 2011 17 5392 5401 10.1158/1078-0432.Ccr-10-3083
Tanaka M et al (2011) Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res Off J Am Assoc Cancer Res 17:5392–5401. 10.1158/1078-0432.Ccr-10-308310.1158/1078-0432.Ccr-10-3083
25. Garnier A Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells Immunol Cell Biol 2016 94 662 672 10.1038/icb.2016.25 26924643
Garnier A et al (2016) Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells. Immunol Cell Biol 94:662–672. 10.1038/icb.2016.2526924643 10.1038/icb.2016.25
26. Butler MO A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4 + T cells restricted by prevalent HLA-DR alleles Int Immunol 2010 22 863 873 10.1093/intimm/dxq440 21059769
Butler MO et al (2010) A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4 + T cells restricted by prevalent HLA-DR alleles. Int Immunol 22:863–873. 10.1093/intimm/dxq44021059769 10.1093/intimm/dxq440
27. Numbenjapon T Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8 + T cells Exp Hematol 2007 35 1083 1090 10.1016/j.exphem.2007.04.007 17588477
Numbenjapon T et al (2007) Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8 + T cells. Exp Hematol 35:1083–1090. 10.1016/j.exphem.2007.04.00717588477 10.1016/j.exphem.2007.04.007
28. Numbenjapon T Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells Leukemia 2006 20 1889 1892 10.1038/sj.leu.2404329 17041638
Numbenjapon T et al (2006) Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20:1889–1892. 10.1038/sj.leu.240432917041638 10.1038/sj.leu.2404329
29. Torikai H A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR Blood 2012 119 5697 5705 10.1182/blood-2012-01-405365 22535661
Torikai H et al (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119:5697–5705. 10.1182/blood-2012-01-40536522535661 10.1182/blood-2012-01-405365
30. Kebriaei P Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies Hum Gene Ther 2012 23 444 450 10.1089/hum.2011.167 22107246
Kebriaei P et al (2012) Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23:444–450. 10.1089/hum.2011.16722107246 10.1089/hum.2011.167
31. Singh H Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies Cancer Res 2011 71 3516 3527 10.1158/0008-5472.Can-10-3843 21558388
Singh H et al (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71:3516–3527. 10.1158/0008-5472.Can-10-384321558388 10.1158/0008-5472.Can-10-3843
32. Singh H Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping Beauty system and artificial antigen presenting cells PLoS One 2013 8 e64138 10.1371/journal.pone.0064138 23741305
Singh H et al (2013) Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping Beauty system and artificial antigen presenting cells. PLoS One 8:e64138. 10.1371/journal.pone.006413823741305 10.1371/journal.pone.0064138
33. Chen L Flies DB Molecular mechanisms of T cell co-stimulation and co-inhibition Nat Rev Immunol 2013 13 227 242 10.1038/nri3405 23470321
Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227–242. 10.1038/nri340523470321 10.1038/nri3405
34. Sharpe AH Mechanisms of costimulation Immunol Rev 2009 229 5 11 10.1111/j.1600-065X.2009.00784.x 19426211
Sharpe AH (2009) Mechanisms of costimulation. Immunol Rev 229:5–11. 10.1111/j.1600-065X.2009.00784.x19426211 10.1111/j.1600-065X.2009.00784.x
35. Watts TH DeBenedette M A. T cell co-stimulatory molecules other than CD28 Curr Opin Immunol 1999 11 286 293 10.1016/s0952-7915(99)80046-6 10375549
Watts TH, DeBenedette M (1999) A. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 11:286–293. 10.1016/s0952-7915(99)80046-610375549 10.1016/s0952-7915(99)80046-6
36. Zha S Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes Immunotherapy 2019 11 967 982 10.2217/imt-2018-0211 31218907
Zha S et al (2019) Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes. Immunotherapy 11:967–982. 10.2217/imt-2018-021131218907 10.2217/imt-2018-0211
37. Tay JCK Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells Mol Ther Methods Clin Dev 2021 21 107 120 10.1016/j.omtm.2021.02.023 33816644
Tay JCK et al (2021) Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells. Mol Ther Methods Clin Dev 21:107–120. 10.1016/j.omtm.2021.02.02333816644 10.1016/j.omtm.2021.02.023
38. Suhoski MM Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules Mol Ther J Am Soc Gene Ther 2007 15 981 988 10.1038/mt.sj.6300134
Suhoski MM et al (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther J Am Soc Gene Ther 15:981–988. 10.1038/mt.sj.630013410.1038/mt.sj.6300134
39. Brentjens RJ Eradication of systemic B-cell tumours by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 2003 9 279 286 10.1038/nm827 12579196
Brentjens RJ et al (2003) Eradication of systemic B-cell tumours by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279–286. 10.1038/nm82712579196 10.1038/nm827
40. Schoenberger SP Efficient direct priming of tumour-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res 1998 58 3094 3100 9679976
Schoenberger SP et al (1998) Efficient direct priming of tumour-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 58:3094–31009679976
41. Cai Z Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8 + T cells Proc Natl Acad Sci USA 1996 93 14736 14741 10.1073/pnas.93.25.14736 8962124
Cai Z et al (1996) Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8 + T cells. Proc Natl Acad Sci USA 93:14736–14741. 10.1073/pnas.93.25.147368962124 10.1073/pnas.93.25.14736
42. Latouche JB Sadelain M Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells Nat Biotechnol 2000 18 405 409 10.1038/74455 10748520
Latouche JB, Sadelain M (2000) Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18:405–409. 10.1038/7445510748520 10.1038/74455
43. Watts TH TNF/TNFR family members in costimulation of T cell responses Annu Rev Immunol 2005 23 23 68 10.1146/annurev.immunol.23.021704.115839 15771565
Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68. 10.1146/annurev.immunol.23.021704.11583915771565 10.1146/annurev.immunol.23.021704.115839
44. Halstead ES Mueller YM Altman JD Katsikis P D. In vivo stimulation of CD137 broadens primary antiviral CD8 + T cell responses Nat Immunol 2002 3 536 541 10.1038/ni798 12021777
Halstead ES, Mueller YM, Altman JD, Katsikis P (2002) D. In vivo stimulation of CD137 broadens primary antiviral CD8 + T cell responses. Nat Immunol 3:536–541. 10.1038/ni79812021777 10.1038/ni798
45. Wilcox RA Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumours J Clin Investig 2002 109 651 659 10.1172/jci14184 11877473
Wilcox RA et al (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumours. J Clin Investig 109:651–659. 10.1172/jci1418411877473 10.1172/jci14184
46. Maus MV Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat Biotechnol 2002 20 143 148 10.1038/nbt0202-143 11821859
Maus MV et al (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20:143–148. 10.1038/nbt0202-14311821859 10.1038/nbt0202-143
47. Thomas AK Maus MV Shalaby WS June CH Riley JL A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes Clin Immunol (Orlando Fla) 2002 105 259 272 10.1006/clim.2002.5277
Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL (2002) A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol (Orlando Fla) 105:259–272. 10.1006/clim.2002.527710.1006/clim.2002.5277
48. Melero I Amplification of tumour immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway Eur J Immunol 1998 Eur J Immunol 1116 1121 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A
Melero I et al (1998) Amplification of tumour immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28:1116–1121. 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A
49. Aerts-Toegaert C CD83 expression on dendritic cells and T cells: correlation with effective immune responses Eur J Immunol 2007 37 686 695 10.1002/eji.200636535 17301951
Aerts-Toegaert C et al (2007) CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol 37:686–695. 10.1002/eji.20063653517301951 10.1002/eji.200636535
50. Prazma CM Yazawa N Fujimoto Y Fujimoto M Tedder TF CD83 expression is a sensitive marker of activation required for B cell and CD4 + T cell longevity in vivo J Immunol (Baltimore Md : 1950) 2007 179 4550 4562 10.4049/jimmunol.179.7.4550
Prazma CM, Yazawa N, Fujimoto Y, Fujimoto M, Tedder TF (2007) CD83 expression is a sensitive marker of activation required for B cell and CD4 + T cell longevity in vivo. J Immunol (Baltimore Md : 1950) 179:4550–4562. 10.4049/jimmunol.179.7.455010.4049/jimmunol.179.7.4550
51. Deeths MJ Mescher MF ICAM-1 and B7-1 provide similar but distinct costimulation for CD8 + T cells, while CD4 + T cells are poorly costimulated by ICAM-1 Eur J Immunol) 1999 29 45 53 10.4049/jimmunol.179.7.4550 9933085
Deeths MJ, Mescher MF (1999) ICAM-1 and B7-1 provide similar but distinct costimulation for CD8 + T cells, while CD4 + T cells are poorly costimulated by ICAM-1. Eur J Immunol 29:45–53. 10.1002/(SICI)1521-4141(199901)29:013.0.CO;2-I9933085 10.4049/jimmunol.179.7.4550
52. Parra E Wingren AG Hedlund G Kalland T Dohlsten M The role of B7-1 and LFA-3 in costimulation of CD8 + T cells J Immunol (Baltimore, Md: 1950) 1997 158 637 642 10.4049/jimmunol.158.2.637
Parra E, Wingren AG, Hedlund G, Kalland T, Dohlsten M (1997) The role of B7-1 and LFA-3 in costimulation of CD8 + T cells. J Immunol (Baltimore, Md: 1950) 158:637–64210.4049/jimmunol.158.2.637
53. Zhou Y Interleukin 15 in cell-based cancer immunotherapy Int J Mol Sci 2022 10.3390/ijms23137311 36614159
Zhou Y et al (2022) Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 10.3390/ijms2313731136614159 10.3390/ijms23137311
54. Morgan DA Ruscetti FW Gallo R Selective in vitro growth of T lymphocytes from normal human bone marrows Science (New York N Y) 1976 193 1007 1008 10.1126/science.181845 181845
Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (New York N Y) 193:1007–1008. 10.1126/science.181845181845 10.1126/science.181845
55. Siegel JP Sharon M Smith PL Leonard WJ The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities Science (New York N Y) 1987 238 75 78 10.1126/science.3116668 3116668
Siegel JP, Sharon M, Smith PL, Leonard WJ (1987) The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science (New York N Y) 238:75–78. 10.1126/science.31166683116668 10.1126/science.3116668
56. Mingari MC Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells Nature 1984 312 641 643 10.1038/312641a0 6438535
Mingari MC et al (1984) Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 312:641–643. 10.1038/312641a06438535 10.1038/312641a0
57. Lenardo M Mature T lymphocyte apoptosis–immune regulation in a dynamic and unpredictable antigenic environment Annu Rev Immunol 1999 17 221 253 10.1146/annurev.immunol.17.1.221 10358758
Lenardo M et al (1999) Mature T lymphocyte apoptosis–immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221–253. 10.1146/annurev.immunol.17.1.22110358758 10.1146/annurev.immunol.17.1.221
58. Berard M Brandt K Bulfone-Paus S Tough DF IL-15 promotes the survival of naive and memory phenotype CD8 + T cells J Immunol (Baltimore Md: 1950) 2003 170 5018 5026 10.4049/jimmunol.170.10.5018
Berard M, Brandt K, Bulfone-Paus S, Tough DF (2003) IL-15 promotes the survival of naive and memory phenotype CD8 + T cells. J Immunol (Baltimore Md: 1950) 170:5018–5026. 10.4049/jimmunol.170.10.501810.4049/jimmunol.170.10.5018
59. Parrish-Novak J Foster DC Holly RD Clegg CH Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses J Leukoc Biol 2002 72 856 863 10.1189/jlb.72.5.856 12429707
Parrish-Novak J, Foster DC, Holly RD, Clegg CH (2002) Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72:856–86312429707 10.1189/jlb.72.5.856
60. Strengell M Sareneva T Foster D Julkunen I Matikainen S IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response J Immunol (Baltimore Md: 1950) 2002 169 3600 3605 10.4049/jimmunol.169.7.3600
Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S (2002) IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol (Baltimore Md: 1950) 169:3600–3605. 10.4049/jimmunol.169.7.360010.4049/jimmunol.169.7.3600
61. Rochman Y Spolski R Leonard WJ New insights into the regulation of T cells by gamma(c) family cytokines Nat Rev Immunol 2009 9 480 490 10.1038/nri2580 19543225
Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480–490. 10.1038/nri258019543225 10.1038/nri2580
62. Li J Co-infusion of CAR-T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumour efficacy in mice Cancer Lett 2023 568 216287 10.1016/j.canlet.2023.216287 37392990
Li J et al (2023) Co-infusion of CAR-T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumour efficacy in mice. Cancer Lett 568:216287. 10.1016/j.canlet.2023.21628737392990 10.1016/j.canlet.2023.216287
63. Imai C Iwamoto S Campana D Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood 2005 106 376 383 10.1182/blood-2004-12-4797 15755898
Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376–383. 10.1182/blood-2004-12-479715755898 10.1182/blood-2004-12-4797
64. Lapteva N Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications Cytotherapy 2012 14 1131 1143 10.3109/14653249.2012.700767 22900959
Lapteva N et al (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14:1131–1143. 10.3109/14653249.2012.70076722900959 10.3109/14653249.2012.700767
65. Liu Y Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy Clin Cancer Res Off J Am Assoc Cancer Res 2013 19 2132 2143 10.1158/1078-0432.Ccr-12-1243
Liu Y et al (2013) Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res Off J Am Assoc Cancer Res 19:2132–2143. 10.1158/1078-0432.Ccr-12-124310.1158/1078-0432.Ccr-12-1243
66. Cheever MA Higano CS PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Clin Cancer Res Off J Am Assoc Cancer Res 2011 17 3520 3526 10.1158/1078-0432.Ccr-10-3126
Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res Off J Am Assoc Cancer Res 17:3520–3526. 10.1158/1078-0432.Ccr-10-312610.1158/1078-0432.Ccr-10-3126
67. Yee C Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumour effect of transferred T cells Proc Natl Acad Sci USA 2002 99 16168 16173 10.1073/pnas.242600099 12427970
Yee C et al (2002) Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumour effect of transferred T cells. Proc Natl Acad Sci USA 99:16168–16173. 10.1073/pnas.24260009912427970 10.1073/pnas.242600099
68. Almand B Clinical significance of defective dendritic cell differentiation in cancer Clin Cancer Res Off J Am Assoc Cancer Res 2000 6 1755 1766
Almand B et al (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res Off J Am Assoc Cancer Res 6:1755–1766
69. Satthaporn S Dendritic cells are dysfunctional in patients with operable breast cancer Cancer Immunol Immunother CII 2004 53 510 518 10.1007/s00262-003-0485-5 14740176
Satthaporn S et al (2004) Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother CII 53:510–518. 10.1007/s00262-003-0485-514740176 10.1007/s00262-003-0485-5
70. Yang Y Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules J Biol Chem 1992 267 11669 11672 10.1016/S0021-9258(19)49745-7 1339432
Yang Y et al (1992) Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J Biol Chem 267:11669–116721339432 10.1016/S0021-9258(19)49745-7
71. Jackson MR Song ES Yang Y Peterson PA Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells Proc Natl Acad Sci USA 1992 89 12117 12121 10.1073/pnas.89.24.12117 1465448
Jackson MR, Song ES, Yang Y, Peterson PA (1992) Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci USA 89:12117–12121. 10.1073/pnas.89.24.121171465448 10.1073/pnas.89.24.12117
72. Mitchell MS Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope J Clin Oncol Off J Am Soc Clin Oncol 2002 20 1075 1086 10.1200/jco.2002.20.4.1075
Mitchell MS et al (2002) Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol Off J Am Soc Clin Oncol 20:1075–1086. 10.1200/jco.2002.20.4.107510.1200/jco.2002.20.4.1075
73. Papanicolaou GA Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele Blood 2003 102 2498 2505 10.1182/blood-2003-02-0345 12805061
Papanicolaou GA et al (2003) Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102:2498–2505. 10.1182/blood-2003-02-034512805061 10.1182/blood-2003-02-0345
74. Krause A Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J Exp Med 1998 188 619 626 10.1084/jem.188.4.619 9705944
Krause A et al (1998) Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188:619–626. 10.1084/jem.188.4.6199705944 10.1084/jem.188.4.619
75. Sprent J Antigen-presenting cells. Professionals and amateurs Curr Biol CB 1995 5 1095 1097 10.1016/s0960-9822(95)00219-3 8548275
Sprent J (1995) Antigen-presenting cells. Professionals and amateurs. Curr Biol CB 5:1095–1097. 10.1016/s0960-9822(95)00219-38548275 10.1016/s0960-9822(95)00219-3
76. Mellman I Turley SJ Steinman RM Antigen processing for amateurs and professionals Trends Cell Biol 1998 8 231 237 10.1016/s0962-8924(98)01276-8 9695847
Mellman I, Turley SJ, Steinman RM (1998) Antigen processing for amateurs and professionals. Trends Cell Biol 8:231–237. 10.1016/s0962-8924(98)01276-89695847 10.1016/s0962-8924(98)01276-8
77. Zhong XS Matsushita M Plotkin J Riviere I Sadelain M Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8 + T cell-mediated tumour eradication Mol Ther J Am Soc Gene Ther 2010 18 413 420 10.1038/mt.2009.210
Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8 + T cell-mediated tumour eradication. Mol Ther J Am Soc Gene Ther 18:413–420. 10.1038/mt.2009.21010.1038/mt.2009.210
78. Laskowski TJ Biederstädt A Rezvani K Natural killer cells in antitumour adoptive cell immunotherapy Nat Rev Cancer 2022 22 557 575 10.1038/s41568-022-00491-0 35879429
Laskowski TJ, Biederstädt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22:557–575. 10.1038/s41568-022-00491-035879429 10.1038/s41568-022-00491-0
79. Ding Q RAFTsomes containing epitope-MHC-II complexes mediated CD4 + T cell activation and antigen-specific immune responses Pharm Res 2013 30 60 69 10.1007/s11095-012-0849-7 22878683
Ding Q et al (2013) RAFTsomes containing epitope-MHC-II complexes mediated CD4 + T cell activation and antigen-specific immune responses. Pharm Res 30:60–69. 10.1007/s11095-012-0849-722878683 10.1007/s11095-012-0849-7
80. Zappasodi R The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumour T cells Haematologica 2008 93 1523 1534 10.3324/haematol.12521 18728033
Zappasodi R et al (2008) The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumour T cells. Haematologica 93:1523–1534. 10.3324/haematol.1252118728033 10.3324/haematol.12521
81. Wang C Sun W Ye Y Bomba HN Gu Z Bioengineering of artificial antigen presenting cells and lymphoid organs Theranostics 2017 7 3504 3516 10.7150/thno.19017 28912891
Wang C, Sun W, Ye Y, Bomba HN, Gu Z (2017) Bioengineering of artificial antigen presenting cells and lymphoid organs. Theranostics 7:3504–3516. 10.7150/thno.1901728912891 10.7150/thno.19017
82. Hu CM Nanoparticle biointerfacing by platelet membrane cloaking Nature 2015 526 118 121 10.1038/nature15373 26374997
Hu CM et al (2015) Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526:118–121. 10.1038/nature1537326374997 10.1038/nature15373
83. Fang RH Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery Nano Lett 2014 14 2181 2188 10.1021/nl500618u 24673373
Fang RH et al (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14:2181–2188. 10.1021/nl500618u24673373 10.1021/nl500618u
84. Mescher MF Savelieva E Stimulation of tumour-specific immunity using tumour cell plasma membrane antigen Methods (San Diego Calif) 1997 12 155 164 10.1006/meth.1997.0466 9184379
Mescher MF, Savelieva E (1997) Stimulation of tumour-specific immunity using tumour cell plasma membrane antigen. Methods (San Diego Calif) 12:155–164. 10.1006/meth.1997.04669184379 10.1006/meth.1997.0466
85. Wolfers J Tumour-derived exosomes are a source of shared tumour rejection antigens for CTL cross-priming Nat Med 2001 7 297 303 10.1038/85438 11231627
Wolfers J et al (2001) Tumour-derived exosomes are a source of shared tumour rejection antigens for CTL cross-priming. Nat Med 7:297–303. 10.1038/8543811231627 10.1038/85438
86. Raposo G B lymphocytes secrete antigen-presenting vesicles J Exp Med 1996 183 1161 1172 10.1084/jem.183.3.1161 8642258
Raposo G et al (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183:1161–1172. 10.1084/jem.183.3.11618642258 10.1084/jem.183.3.1161
87. Théry C Zitvogel L Amigorena S Exosomes: composition, biogenesis and function Nat Rev Immunol 2002 2 569 579 10.1038/nri855 12154376
Théry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579. 10.1038/nri85512154376 10.1038/nri855
88. Hwang I Shen X Sprent J Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules Proc Natl Acad Sci USA 2003 100 6670 6675 10.1073/pnas.1131852100 12743365
Hwang I, Shen X, Sprent J (2003) Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA 100:6670–6675. 10.1073/pnas.113185210012743365 10.1073/pnas.1131852100
89. Curtsinger JM Inflammatory cytokines provide a third signal for activation of naive CD4 + and CD8 + T cells J Immunol (Baltimore, Md: 1950) 1999 162 3256 3262 10.4049/jimmunol.162.6.3256
Curtsinger JM et al (1999) Inflammatory cytokines provide a third signal for activation of naive CD4 + and CD8 + T cells. J Immunol (Baltimore, Md: 1950) 162:3256–326210.4049/jimmunol.162.6.3256
90. Kosmides AK Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma Biomaterials 2017 118 16 26 10.1016/j.biomaterials.2016.11.038 27940380
Kosmides AK et al (2017) Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials 118:16–26. 10.1016/j.biomaterials.2016.11.03827940380 10.1016/j.biomaterials.2016.11.038
91. Steenblock ER Fahmy TM A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells Mol Ther J Am Soc Gene Ther 2008 16 765 772 10.1038/mt.2008.11
Steenblock ER, Fahmy TM (2008) A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther J Am Soc Gene Ther 16:765–772. 10.1038/mt.2008.1110.1038/mt.2008.11
92. Champion JA Katare YK Mitragotri S Making polymeric micro- and nanoparticles of complex shapes Proc Natl Acad Sci USA 2007 104 11901 11904 10.1073/pnas.0705326104 17620615
Champion JA, Katare YK, Mitragotri S (2007) Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci USA 104:11901–11904. 10.1073/pnas.070532610417620615 10.1073/pnas.0705326104
93. Meyer RA Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation Small 2015 11 1519 1525 10.1002/smll.201402369 25641795
Meyer RA et al (2015) Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small 11:1519–1525. 10.1002/smll.20140236925641795 10.1002/smll.201402369
94. Fadel TR A carbon nanotube-polymer composite for T-cell therapy Nat Nanotechnol 2014 9 639 647 10.1038/nnano.2014.154 25086604
Fadel TR et al (2014) A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol 9:639–647. 10.1038/nnano.2014.15425086604 10.1038/nnano.2014.154
95. Porter DL A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation Blood 2006 107 1325 1331 10.1182/blood-2005-08-3373 16269610
Porter DL et al (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107:1325–1331. 10.1182/blood-2005-08-337316269610 10.1182/blood-2005-08-3373
96. Laport GG Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation Blood 2003 102 2004 2013 10.1182/blood-2003-01-0095 12763934
Laport GG et al (2003) Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102:2004–2013. 10.1182/blood-2003-01-009512763934 10.1182/blood-2003-01-0095
97. Fadel TR Fahmy TM Immunotherapy applications of carbon nanotubes: from design to safe applications Trends Biotechnol 2014 32 198 209 10.1016/j.tibtech.2014.02.005 24630474
Fadel TR, Fahmy TM (2014) Immunotherapy applications of carbon nanotubes: from design to safe applications. Trends Biotechnol 32:198–209. 10.1016/j.tibtech.2014.02.00524630474 10.1016/j.tibtech.2014.02.005
98. Fadel TR Clustering of stimuli on single-walled carbon nanotube bundles enhances cellular activation Langmuir 2010 26 5645 5654 10.1021/la902068z 19764784
Fadel TR et al (2010) Clustering of stimuli on single-walled carbon nanotube bundles enhances cellular activation. Langmuir 26:5645–5654. 10.1021/la902068z19764784 10.1021/la902068z
99. Alshehri R Carbon nanotubes in biomedical applications: factors, mechanisms, and remedies of toxicity J Med Chem 2016 59 8149 8167 10.1021/acs.jmedchem.5b01770 27142556
Alshehri R et al (2016) Carbon nanotubes in biomedical applications: factors, mechanisms, and remedies of toxicity. J Med Chem 59:8149–8167. 10.1021/acs.jmedchem.5b0177027142556 10.1021/acs.jmedchem.5b01770
100. Eggermont LJ Paulis LE Tel J Figdor CG Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells Trends Biotechnol 2014 32 456 465 10.1016/j.tibtech.2014.06.007 24998519
Eggermont LJ, Paulis LE, Tel J, Figdor CG (2014) Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol 32:456–465. 10.1016/j.tibtech.2014.06.00724998519 10.1016/j.tibtech.2014.06.007
101. Hou F Guo Z Ho MT Hui Y Zhao CX Particle-based artificial antigen-presenting cell systems for T cell activation in adoptive T cell therapy ACS Nano 2024 18 8571 8599 10.1021/acsnano.3c10180 38483840
Hou F, Guo Z, Ho MT, Hui Y, Zhao CX (2024) Particle-based artificial antigen-presenting cell systems for T cell activation in adoptive T cell therapy. ACS Nano 18:8571–8599. 10.1021/acsnano.3c1018038483840 10.1021/acsnano.3c10180
102. Kagoya Y Transient stimulation expands superior antitumour T cells for adoptive therapy JCI Insight 2017 2 e89580 10.1172/jci.insight.89580 28138559
Kagoya Y et al (2017) Transient stimulation expands superior antitumour T cells for adoptive therapy. JCI Insight 2:e89580. 10.1172/jci.insight.8958028138559 10.1172/jci.insight.89580
103. Garson D Dokhélar MC Wakasugi H Mishal Z Tursz T HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon Exp Hematol 1985 13 885 890 3930277
Garson D, Dokhélar MC, Wakasugi H, Mishal Z, Tursz T (1985) HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. Exp Hematol 13:885–8903930277
104. Moitreyee CK Suraksha A Swarup AS Potential role of NF-kB and RXR beta like proteins in interferon induced HLA class I and beta globin gene transcription in K562 erythroleukaemia cells Mol Cell Biochem 1998 178 103 112 10.1023/a:1006816806138 9546588
Moitreyee CK, Suraksha A, Swarup AS (1998) Potential role of NF-kB and RXR beta like proteins in interferon induced HLA class I and beta globin gene transcription in K562 erythroleukaemia cells. Mol Cell Biochem 178:103–112. 10.1023/a:10068168061389546588 10.1023/a:1006816806138
105. Huls MH Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood J Vis Exp JoVE 2013 10.3791/50070 23407473
Huls MH et al (2013) Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp JoVE. 10.3791/5007023407473 10.3791/50070
106. Seimetz D Heller K Richter J Approval of First CAR-Ts: have we solved all hurdles for ATMPs? Cell Med 2019 11 2155179018822781 10.1177/2155179018822781 32634192
Seimetz D, Heller K, Richter J (2019) Approval of First CAR-Ts: have we solved all hurdles for ATMPs? Cell Med 11:2155179018822781. 10.1177/215517901882278132634192 10.1177/2155179018822781
107. Stroncek DF Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells Cytotherapy 2016 18 893 901 10.1016/j.jcyt.2016.04.003 27210719
Stroncek DF et al (2016) Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy 18:893–901. 10.1016/j.jcyt.2016.04.00327210719 10.1016/j.jcyt.2016.04.003
108. Schmidts A Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources J Immunother Cancer 2020 10.1136/jitc-2020-000990 32900862
Schmidts A et al (2020) Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer. 10.1136/jitc-2020-00099032900862 10.1136/jitc-2020-000990
109. Dodo K An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking PLoS One 2014 9 e86275 10.1371/journal.pone.0086275 24454964
Dodo K et al (2014) An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS One 9:e86275. 10.1371/journal.pone.008627524454964 10.1371/journal.pone.0086275
110. Wu Z Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes J Virol 2006 80 11393 11397 10.1128/jvi.01288-06 16943302
Wu Z et al (2006) Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol 80:11393–11397. 10.1128/jvi.01288-0616943302 10.1128/jvi.01288-06
111. Shrestha B Generation of antitumour T cells for adoptive cell therapy with artificial antigen presenting cells J Immunother (Hagerstown Md: 1997) 2020 43 79 88 10.1097/cji.0000000000000306
Shrestha B et al (2020) Generation of antitumour T cells for adoptive cell therapy with artificial antigen presenting cells. J Immunother (Hagerstown Md: 1997) 43:79–88. 10.1097/cji.000000000000030610.1097/cji.0000000000000306
112. Zhao Y Tumour infiltrating lymphocyte (TIL) therapy for solid Tumour treatment: progressions and challenges Cancers 2022 10.3390/cancers14174160 36612279
Zhao Y et al (2022) Tumour infiltrating lymphocyte (TIL) therapy for solid Tumour treatment: progressions and challenges. Cancers. 10.3390/cancers1417416036612279 10.3390/cancers14174160
113. Besser MJ Clinical responses in a phase II study using adoptive transfer of short-term cultured tumour infiltration lymphocytes in metastatic melanoma patients Clin Cancer Res Off J Am Assoc Cancer Res 2010 16 2646 2655 10.1158/1078-0432.Ccr-10-0041
Besser MJ et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumour infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 16:2646–2655. 10.1158/1078-0432.Ccr-10-004110.1158/1078-0432.Ccr-10-0041
114. Radvanyi LG Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumour-infiltrating lymphocytes in metastatic melanoma patients Clin Cancer Res Off J Am Assoc Cancer Res 2012 18 6758 6770 10.1158/1078-0432.Ccr-12-1177
Radvanyi LG et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumour-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 18:6758–6770. 10.1158/1078-0432.Ccr-12-117710.1158/1078-0432.Ccr-12-1177
115. Butler MO Ex vivo expansion of human CD8 + T cells using autologous CD4 + T cell help PLoS One 2012 7 e30229 10.1371/journal.pone.0030229 22279573
Butler MO et al (2012) Ex vivo expansion of human CD8 + T cells using autologous CD4 + T cell help. PLoS One 7:e30229. 10.1371/journal.pone.003022922279573 10.1371/journal.pone.0030229
116. Santegoets SJ IL-21 promotes the expansion of CD27 + CD28 + tumour infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells J Transl Med 2013 11 37 10.1186/1479-5876-11-37 23402380
Santegoets SJ et al (2013) IL-21 promotes the expansion of CD27 + CD28 + tumour infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 11:37. 10.1186/1479-5876-11-3723402380 10.1186/1479-5876-11-37
117. Ye Q Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumour infiltrating lymphocytes J Transl Med 2011 10.1186/1479-5876-9-131 22082029
Ye Q et al (2011) Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumour infiltrating lymphocytes. J Transl Med. 10.1186/1479-5876-9-13122082029 10.1186/1479-5876-9-131
118. Melief CJ Kast WM T-cell immunotherapy of tumours by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes Immunol Rev 1995 145 167 177 10.1111/j.1600-065x.1995.tb00081.x 7590825
Melief CJ, Kast WM (1995) T-cell immunotherapy of tumours by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167–177. 10.1111/j.1600-065x.1995.tb00081.x7590825 10.1111/j.1600-065x.1995.tb00081.x
119. Sun S Dual function of Drosophila cells as APCs for naive CD8 + T cells: implications for tumour immunotherapy Immunity 1996 4 555 564 10.1016/s1074-7613(00)80482-3 8673702
Sun S et al (1996) Dual function of Drosophila cells as APCs for naive CD8 + T cells: implications for tumour immunotherapy. Immunity 4:555–564. 10.1016/s1074-7613(00)80482-38673702 10.1016/s1074-7613(00)80482-3
120. Benz EJ Jr Embryonic-fetal erythroid characteristics of a human leukemic cell line Proc Natl Acad Sci USA 1980 77 3509 3513 10.1073/pnas.77.6.3509 6932034
Benz EJ Jr. et al (1980) Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proc Natl Acad Sci USA 77:3509–3513. 10.1073/pnas.77.6.35096932034 10.1073/pnas.77.6.3509
121. Lozzio CB Lozzio BB Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome Blood 1975 45 321 334 10.1182/blood.V45.3.321.321 163658
Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321–334163658 10.1182/blood.V45.3.321.321
122. Rossjohn J Pellicci DG Patel O Gapin L Godfrey DI Recognition of CD1d-restricted antigens by natural killer T cells Nat Rev Immunol 2012 12 845 857 10.1038/nri3328 23154222
Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI (2012) Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol 12:845–857. 10.1038/nri332823154222 10.1038/nri3328
123. Brennan PJ Brigl M Brenner MB Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions Nat Rev Immunol 2013 13 101 117 10.1038/nri3369 23334244
Brennan PJ, Brigl M, Brenner MB (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13:101–117. 10.1038/nri336923334244 10.1038/nri3369
124. Imataki O Endogenous ligands selectively stimulate highly avid autoreactive human invariant natural killer T cells with distinctive T-cell receptor Vβ11 CDR3 sequence motifs Blood 2011 118 999 10.1182/blood.V118.21.999.999
Imataki O et al (2011) Endogenous ligands selectively stimulate highly avid autoreactive human invariant natural killer T cells with distinctive T-cell receptor Vβ11 CDR3 sequence motifs. Blood 118:999. 10.1182/blood.V118.21.999.99910.1182/blood.V118.21.999.999
125. Nakamura T Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders Br J Ophthalmol 2004 88 1280 1284 10.1136/bjo.2003.038497 15377551
Nakamura T et al (2004) Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. Br J Ophthalmol 88:1280–1284. 10.1136/bjo.2003.03849715377551 10.1136/bjo.2003.038497
126. Smith BD K562/GM-CSF immunotherapy reduces tumour burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate Clin Cancer Res Off J Am Assoc Cancer Res 2010 16 338 347 10.1158/1078-0432.Ccr-09-2046
Smith BD et al (2010) K562/GM-CSF immunotherapy reduces tumour burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res Off J Am Assoc Cancer Res 16:338–347. 10.1158/1078-0432.Ccr-09-204610.1158/1078-0432.Ccr-09-2046
127. Fujisaki H Expansion of highly cytotoxic human natural killer cells for cancer cell therapy Cancer Res 2009 69 4010 4017 10.1158/0008-5472.Can-08-3712 19383914
Fujisaki H et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010–4017. 10.1158/0008-5472.Can-08-371219383914 10.1158/0008-5472.Can-08-3712
128. Somanchi SS Senyukov VV Denman CJ Lee DA Expansion, purification, and functional assessment of human peripheral blood NK cells J Vis Exp JoVE 2011 10.3791/2540 21339714
Somanchi SS, Senyukov VV, Denman CJ, Lee DA (2011) Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp JoVE. 10.3791/254021339714 10.3791/2540
129. Denman CJ Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells PLoS One 2012 7 e30264 10.1371/journal.pone.0030264 22279576
Denman CJ et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7:e30264. 10.1371/journal.pone.003026422279576 10.1371/journal.pone.0030264
130. Hippen KL Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity Sci Transl Med 2011 3 83ra41 10.1126/scitranslmed.3001809 21593401
Hippen KL et al (2011) Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 3:83ra41. 10.1126/scitranslmed.300180921593401 10.1126/scitranslmed.3001809
131. Kim JV Latouche JB Rivière I Sadelain M The ABCs of artificial antigen presentation Nat Biotechnol 2004 22 403 410 10.1038/nbt955 15060556
Kim JV, Latouche JB, Rivière I, Sadelain M (2004) The ABCs of artificial antigen presentation. Nat Biotechnol 22:403–410. 10.1038/nbt95515060556 10.1038/nbt955
